Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ESPR Stock Forecast 2026-2027
$2.04
Current Price
$523.89M
Market Cap
Buy 5
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to ESPR Price Targets
+684.3%
To High Target of $16.00
+152.9%
To Median Target of $5.16
-12.7%
To Low Target of $1.78
ESPR Price Momentum
-8.1%
1 Week Change
-20.0%
1 Month Change
+114.7%
1 Year Change
-44.9%
Year-to-Date Change
-51.2%
From 52W High of $4.18
+195.7%
From 52W Low of $0.69
📊 TOP ANALYST CALLS
Did ESPR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Esperion is one of their latest high-conviction picks.
Latest ESPR Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, ESPR has a bullish consensus with a median price target of $5.16 (ranging from $1.78 to $16.00). The overall analyst rating is Buy (7.7/10). Currently trading at $2.04, the median forecast implies a 152.9% upside. This outlook is supported by 5 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 684.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ESPR Analyst Ratings
5
Buy
1
Hold
1
Sell
ESPR Price Target Range
Low
$1.78
Average
$5.16
High
$16.00
Current: $2.04
Latest ESPR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ESPR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2026 | Citizens | Jason N. Butler | Market Outperform | Maintains | $5.00 |
| Mar 3, 2026 | Needham | Serge Belanger | Buy | Maintains | $5.00 |
| Nov 25, 2025 | Piper Sandler | David Amsellem | Overweight | Initiates | $9.00 |
| Sep 19, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Jun 17, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| May 7, 2025 | Needham | Serge Belanger | Buy | Maintains | $4.00 |
| Apr 25, 2025 | Needham | Serge Belanger | Buy | Reiterates | $5.00 |
| Apr 25, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Apr 17, 2025 | Goldman Sachs | Paul Choi | Neutral | Maintains | $3.00 |
| Apr 8, 2025 | Needham | Serge Belanger | Buy | Reiterates | $5.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Mar 5, 2025 | Citizens Capital Markets | Jason Butler | Market Outperform | Reiterates | $4.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Feb 11, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $4.00 |
| Feb 11, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Jan 23, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $7.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 10, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $N/A |
| Dec 18, 2024 | Goldman Sachs | Paul Choi | Neutral | Reinstates | $4.00 |
Esperion Therapeutics Inc. (ESPR) Competitors
The following stocks are similar to Esperion based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Esperion Therapeutics Inc. (ESPR) Financial Data
Esperion Therapeutics Inc. has a market capitalization of $523.89M with a P/E ratio of -18.5x. The company generates $403.14M in trailing twelve-month revenue with a -5.6% profit margin.
Revenue growth is +143.7% quarter-over-quarter, while maintaining an operating margin of +50.6% and return on equity of +7.5%.
Valuation Metrics
Market Cap
$523.89M
Enterprise Value
$904.04M
P/E Ratio
-18.5x
PEG Ratio
0.1x
Price/Sales
1.3x
Growth & Margins
Revenue Growth (YoY)
+143.7%
Gross Margin
+83.5%
Operating Margin
+50.6%
Net Margin
-5.6%
EPS Growth
+143.7%
Financial Health
Cash/Price Ratio
+32.1%
Current Ratio
1.5x
Debt/Equity
-1.8x
ROE
+7.5%
ROA
+9.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Esperion Therapeutics Inc. (ESPR) Business Model
About Esperion Therapeutics Inc.
What They Do
Develops non-statin cholesterol-lowering medications.
Business Model
Esperion Therapeutics generates revenue by developing and commercializing innovative oral medications aimed at lowering low-density lipoprotein cholesterol (LDL-C) in patients. Its main products, NEXLETOL and NEXLIZET, target individuals with conditions like primary hyperlipidemia and cardiovascular disease who are unable to tolerate traditional statin therapies. The company also benefits from strategic partnerships that expand its market presence globally.
Additional Information
Founded in 1998 and headquartered in Ann Arbor, Michigan, Esperion operates within the cardiovascular health segment, focusing on improving treatment options for patients with elevated cholesterol levels. The company's efforts aim to address significant treatment gaps in dyslipidemia management, making it a critical player in the pharmaceutical landscape for cardiovascular health.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
304
CEO
Mr. Sheldon L. Koenig M.B.A.
Country
United States
IPO Year
2013
Website
www.esperion.comEsperion Therapeutics Inc. (ESPR) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Apr 09, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Esperion Therapeutics (ESPR) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for the stock's trajectory.
Why It Matters
Esperion's recent earnings report may influence its stock performance, affecting investor sentiment and potential volatility as market reactions unfold.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Enbumyst, the first FDA-approved nasal spray loop diuretic, is now part of Esperion’s cardiovascular franchise, expected to enhance portfolio growth and revenue.
Why It Matters
Enbumyst's FDA approval enhances Esperion's product lineup, potentially boosting revenue and market position, signaling growth prospects for investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Athyrium Capital Management has entered a $50 million royalty financing agreement with Esperion Therapeutics, acquiring 100% of its royalty interest from Otsuka on bempedoic acid sales in Japan.
Why It Matters
A $50 million royalty financing deal enhances Esperion's liquidity and funds growth potential, impacting share value and investor confidence in the company's future.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bempedoic Acid has received strong endorsement from the AHA/ACC Multisociety Guideline for use in patients with statin intolerance and severe hypercholesterolemia.
Why It Matters
Bempedoic Acid's strong endorsement indicates potential increased demand and market share, boosting investor confidence in the pharmaceutical company behind it.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Esperion Therapeutics, Inc. (ESPR) conducted its Q4 2025 earnings call, discussing financial performance and company developments. Further details can be found in the transcript.
Why It Matters
Esperion's Q4 2025 earnings call reveals financial performance, future guidance, and strategic plans, directly impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
1 month ago
Quick Summary
FY25 Total Revenue increased 21% year-over-year to $403.1 million, with U.S. Net Product Revenue rising 38% to $159.6 million.
Why It Matters
Strong revenue growth indicates robust demand and potential market expansion, signaling positive financial health and future profitability for the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ESPR Stock
What is Esperion Therapeutics Inc.'s (ESPR) stock forecast for 2026?
Based on our analysis of 22 Wall Street analysts, Esperion Therapeutics Inc. (ESPR) has a median price target of $5.16. The highest price target is $16.00 and the lowest is $1.78.
Is ESPR stock a good investment in 2026?
According to current analyst ratings, ESPR has 5 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $2.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ESPR stock?
Wall Street analysts predict ESPR stock could reach $5.16 in the next 12 months. This represents a 152.9% increase from the current price of $2.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Esperion Therapeutics Inc.'s business model?
Esperion Therapeutics generates revenue by developing and commercializing innovative oral medications aimed at lowering low-density lipoprotein cholesterol (LDL-C) in patients. Its main products, NEXLETOL and NEXLIZET, target individuals with conditions like primary hyperlipidemia and cardiovascular disease who are unable to tolerate traditional statin therapies. The company also benefits from strategic partnerships that expand its market presence globally.
What is the highest forecasted price for ESPR Esperion Therapeutics Inc.?
The highest price target for ESPR is $16.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 684.3% increase from the current price of $2.04.
What is the lowest forecasted price for ESPR Esperion Therapeutics Inc.?
The lowest price target for ESPR is $1.78 from at , which represents a -12.7% decrease from the current price of $2.04.
What is the overall ESPR consensus from analysts for Esperion Therapeutics Inc.?
The overall analyst consensus for ESPR is bullish. Out of 22 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $5.16.
How accurate are ESPR stock price projections?
Stock price projections, including those for Esperion Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 4:09 PM UTC